CorMedix Inc. announced that it has entered into a 5-year commercial supply contract with ARC Dialysis, LLC for the supply of DefenCath (taurolidine and heparin). CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and expects to begin commercialization of the product in the inpatient setting on April 15th. CorMedix is committed to building meaningful long-term relationships with dialysis providers that are dedicated to innovation and infection reduction.

ARC Dialysis, a Miami-based medium-sized dialysis organization, provides inpatient dialysis services to approximately 100 inpatient facilities, and is the operator of 18 outpatient dialysis units throughout Florida. ARC Dialysis' objective is to offer its patients superior care, including innovative technologies and drug products, which is core to its mission of enabling patients to live their healthiest and safest lives while undergoing hemodialysis.